Clinical Trial Update: Phase II Clinical Clical of the Pure Protein Derivatives of BCG [Phase 1]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 1 study evaluating Pure Protein Derivatives of Bacillus Calmette-Guérin for tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Pure Protein Derivatives of BCG (Purified protein derivative of Bacillus Calmette-Guérin)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED